RxDoctor Payments DataLook up a doctor →

Chelsea Berkley, MD

Neurology · Oklahoma City, OKNPI 1770998460

Payments from drug & device makers

$277,160in general payments, 2019–2025

Across 840 payments — averaging $329.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$98K
  • Biogen$96K
  • TG Therapeutics, Inc.$42K
  • Sanofi$18K
  • Amgen$7K
  • Novartis$4K
  • plus $11K from 34 others

What the payments were for

  • Consulting fees$29,90111%
  • Speaking & faculty fees$108,13239%
  • Grants$90,00032%
  • Travel & lodging$22,7988%
  • Food & beverage$26,1189%
  • Education$2110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$277,160 in reported general payments places this provider in the 90th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$1,129,902
Medicare patients
199
Services billed
26,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MavencladCladribine12$987,698
Kesimpta PenOfatumumab78$775,602
AubagioTeriflunomide35$386,623
Rebif RebidoseInterferon Beta-1a/Albumin11$134,933
MayzentSiponimod12$109,281
CopaxoneGlatiramer Acetate19$105,723
Avonex (4 Pack)Interferon Beta-1a13$105,087
Teriflunomide122$70,462
Glatiramer Acetate34$59,832
BotoxOnabotulinumtoxina21$54,276
NuedextaDextromethorphan Hbr/Quinidine30$45,394
Dalfampridine ErDalfampridine133$35,275
Aimovig AutoinjectorErenumab-Aooe23$20,202
SunosiSolriamfetol Hcl22$18,955
Dimethyl Fumarate22$18,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Mavenclad$97,975$987,69812 claims
SanofiAubagio$17,809$386,62335 claims
NovartisMayzent$4,492$109,28112 claims
Teva Pharmaceuticals USA, Inc.Copaxone$607$105,72319 claims
BiogenAvonex (4 Pack)$96,171$105,08713 claims
AbbVieBotox, Qulipta$845$70,29036 claims
Avanir Pharmaceuticals, Inc.Nuedexta$236$45,39430 claims
Axsome Therapeutics, Inc.Sunosi$84$18,95522 claims
Upsher-smith Laboratories LLCTopiramate$13$46333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 152 neurology providers in Oklahoma.

Other neurology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →